Champions Oncology, Inc.
CSBR- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000771856
No open-market purchases or sales by Champions Oncology, Inc. insiders were filed in the last 90 days; 28 institutions reported holding it in 13F filings for Q2 2026, worth $36.3M in total; no superinvestor holds it.
Q4 2025 vs. Q3 2025
How the institutions holding Champions Oncology, Inc. changed between Q3 2025 and Q4 2025.
All holders in Q4 2025All holders in Q3 2025
| Measure | Q3 2025 | Q4 2025 | Change |
|---|---|---|---|
| Holders | 27 | 27 | 0 |
| Shares | 5.66M | 5.75M | +87.6K (+1.5%) |
| Value | $36.7M | $39.7M | +$3.07M (+8.4%) |
New holders (3)
Institutions that held Champions Oncology, Inc. at the end of Q4 2025 but not at the end of Q3 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Mink Brook Asset Management LLC | 80,305 | $554.9K | 0.35% |
| Essex Investment Management Co LLC | 18,249 | $126.1K | 0.02% |
| UBS Group AG | 190 | $1.31K | 0.00% |
Sold out (3)
Institutions that held Champions Oncology, Inc. at the end of Q3 2025 and filed for Q4 2025 without it.
| Institution | Shares, Q3 2025 | Value, Q3 2025 |
|---|---|---|
| Susquehanna International Group, LLP | 19,811 | $128.3K |
| Citadel Advisors LLC | 16,326 | $105.7K |
| Royal Bank of Canada | 6,614 | $43.0K |